Scholars@Duke publication: The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.

The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.

Publication , Conference

Zhao, F; Evans, K; Xiao, C; Holtzhausen, A; Hanks, BA

Published in: Journal for ImmunoTherapy of Cancer

Open Access Copy (Duke)

Duke Scholars

Author Brent A. Hanks Medicine, Medical Oncology

Contributor Brent A. Hanks Medicine, Medical Oncology

Published In

Journal for ImmunoTherapy of Cancer

ISSN

2051-1426

Volume

Issue

4(suppl 1)

Start / End Page

8 / 9

Location

National Harbor, Washington, DC

Publisher

BioMed Central

Conference Name

Society for Immunotherapy of Cancer 2016 Annual Meeting

Related Subject Headings

3211 Oncology and carcinogenesis
3204 Immunology

Citation

APA

Chicago

ICMJE

MLA

NLM

Zhao, F., Evans, K., Xiao, C., Holtzhausen, A., & Hanks, B. A. (n.d.). The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment. In Journal for ImmunoTherapy of Cancer (Vol. 82, pp. 8–9). National Harbor, Washington, DC: BioMed Central.

Zhao, F., K. Evans, C. Xiao, A. Holtzhausen, and B. A. Hanks. “The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.” In Journal for ImmunoTherapy of Cancer, 82:8–9. BioMed Central, n.d.

Zhao F, Evans K, Xiao C, Holtzhausen A, Hanks BA. The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment. In: Journal for ImmunoTherapy of Cancer. BioMed Central; p. 8–9.

Zhao, F., et al. “The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.” Journal for ImmunoTherapy of Cancer, vol. 82, no. 4(suppl 1), BioMed Central, pp. 8–9.

Zhao F, Evans K, Xiao C, Holtzhausen A, Hanks BA. The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment. Journal for ImmunoTherapy of Cancer. BioMed Central; p. 8–9.